Inozyme Pharma to Speak at Jefferies Global Healthcare Conference

BOSTON, May 30, 2024-- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company specialized in rare diseases, has announced that its CEO and Chairman, Doug Treco, Ph.D., will be presenting at the Jefferies Global Healthcare Conference. This presentation is scheduled for Thursday, June 6, 2024, between 12:30 and 12:55 pm ET.

Interested individuals can access a live webcast of the presentation through the Investor Relations section on Inozyme’s official website. Additionally, a replay of the event will be available online for a limited duration.

About Inozyme Pharma

Inozyme Pharma, Inc. is dedicated to the development of innovative therapies targeting rare diseases, particularly those affecting the vasculature, soft tissues, and skeletal system. The company’s flagship project is INZ-701, an enzyme replacement therapy designed to combat pathologic mineralization and intimal proliferation. These conditions can lead to significant health issues in patients, often contributing to severe disease-related morbidity and mortality.

INZ-701 is presently in clinical trials for several conditions, including ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. These diseases are characterized by abnormal mineral deposits in tissues, which can result in significant complications.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!